日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection

一项针对复发性艰难梭菌感染的粪便微生物群活体jslm的3期临床试验中,微生物组组成变化和克隆植入情况

Claypool, Josh; Lindved, Gustav; Myers, Pernille Neve; Ward, Tonya; Nielsen, Henrik Bjørn; Blount, Ken F

Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA) for Preventing Recurrent Clostridioides difficile Infection

粪便微生物群活性制剂(REBYOTA)治疗后微生物组和代谢组的恢复可预防艰难梭菌感染复发

Blount, Ken F; Papazyan, Romeo; Ferdyan, Nicky; Srinivasan, Karthik; Gonzalez, Carlos; Shannon, William D; Fuchs, Bryan C

Decreased Antimicrobial Resistance Gene Richness Following Fecal Microbiota, Live-jslm (REBYOTA®) Administration: Post Hoc Analysis of PUNCH CD3

粪便微生物群 Live-jslm (REBYOTA®) 给药后抗菌素耐药基因丰富度降低:PUNCH CD3 的事后分析

Adamowicz, Elizabeth; Kraft, Colleen S; Ward, Tonya; Mehta, Nirja; Shannon, William D; Mishra, Rohan; Blount, Ken F

Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection.

复发性艰难梭菌感染的试验性微生物活生物治疗递送后人类粪便胆汁酸分析

Papazyan Romeo, Ferdyan Nicky, Srinivasan Karthik, Gonzalez Carlos, Shannon William D, Blount Ken, Fuchs Bryan C

A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL

在 Lucent-2 维持治疗试验中,Mirikizumab 对中重度活动性溃疡性结肠炎患者持续控制症状的疗效

Radjenovic, Jelena; Petrovic, Mira; Barceló, Damiá; Anand, R; Turolla, A; Chinellato, G; Giuliani, R; Sansi, F; Hartman, R; Anand, R; Turolla, A; Chinellato, G; Giuliani, R; Sansi, F; Hartman, R; Good, Steven S; Moussa, Adel; Zhou, Xiao-Jian; Sommadossi, Jean-Pierre; Pietropaolo, Keith; Ferdyan, Nicky; Papazyan, Romeo; Walsh, Dana; Klein, Sarah; Qi, Steve; Blount, Ken; Srinivasan, Karthik; Fuchs, Bryan; Dignass, A; Danese, S; Matsuoka, K; Ferrante, M; Long, M; Redondo, I; Gibble, T H; Moses, R; Li, X; Morris, N; Milch, C; Abreu, M; Jones, J

366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial

366. 肠道菌群与复发性艰难梭菌感染患者健康相关生活质量之间的关联:PUNCH CD3 临床试验的结果

Tooth, Leigh R; Hockey, Richard; Treloar, Susan; McClintock, Christine; Dobson, Annette; Feuerstadt, Paul; Blount, Ken; Guo, Amy; Yang, Min; García-Horton, Viviana; Fillbrunn, Mirko; Tillotson, Glenn S; Gao, Yipeng; Dubberke, Erik R; Garey, Kevin W

2021 J. Leonard Goldner Award Winner: Vancomycin Topically Applied at the Surgical Site Does Not Impair Diabetic Fracture Healing and Dose-Dependently Inhibits Calcified Tissue Formation by Osteoblast Precursors Cells

2021年J. Leonard Goldner奖获得者:万古霉素局部应用于手术部位不会损害糖尿病骨折愈合,并且以剂量依赖的方式抑制成骨细胞前体细胞形成钙化组织

Srivastava, Akhil; Rathore, Shipra; Munshi, Anupama; Ramesh, Rajagopal; Garcia, Daniel; Marder, Ryan S; Nadeau, Nicolas; Richards, Sean; Randazzo, Vincenzo; Maguire, James A; Kraeutler, Matthew J; Pierce, Casey; Festa, Anthony; Scillia, Anthony; Feuerstadt, Paul; Blount, Ken; Guo, Amy; Yang, Min; García-Horton, Viviana; Fillbrunn, Mirko; Tillotson, Glenn S; Gao, Yipeng; Dubberke, Erik R; Garey, Kevin W; Feuerstadt, Paul; Dubberke, Erik R; Guo, Amy; Harvey, Adam; Yang, Min; García-Horton, Viviana; Fillbrunn, Mirko; Tillotson, Glenn S; Bancke, Lindy; Garey, Kevin W; Hernandez, Alexis; Rahman, Ohidur; Kadkoy, Yazan; Lauritsen, Katherine L; Sanchez, Alexandra; Innella, Kevin; Lin, Anthony; O'Connor, J Patrick; Benevenia, Joseph; Paglia, David; Lin, Sheldon S; Cottrell, Jessica A

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

RBX2660治疗后艰难梭菌感染复发率显著降低,肠道菌群恢复功能得以持久恢复:一项开放标签的II期临床试验结果

Orenstein, Robert; Dubberke, Erik R; Khanna, Sahil; Lee, Christine H; Yoho, David; Johnson, Stuart; Hecht, Gail; DuPont, Herbert L; Gerding, Dale N; Blount, Ken F; Mische, Sarah; Harvey, Adam

RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections

RBX7455 是一种非冷冻、口服的在研活生物疗法,在一项针对复发性艰难梭菌感染的 1 期研究中,该疗法安全有效,并能改变患者的微生物群。

Khanna, Sahil; Pardi, Darrell S; Jones, Courtney; Shannon, William D; Gonzalez, Carlos; Blount, Ken

Development and Validation of a Novel Microbiome-Based Biomarker of Post-antibiotic Dysbiosis and Subsequent Restoration

开发和验证一种基于微生物组的新型生物标志物,用于检测抗生素后菌群失调及其后续恢复情况

Blount, Ken; Jones, Courtney; Walsh, Dana; Gonzalez, Carlos; Shannon, William D